Artigos de revistas sobre o tema "Gcb-Dlbcl"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Gcb-Dlbcl".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Pukiat, Sulada, Nuttapong Ngamphaiboon, Pooja Advani, Julio Chavez, George Deeb, Anjana Elefante e Francisco J. Hernandez-Ilizaliturri. "BCL-2 Expression at the Time of Diagnosis Affects the Clinical Outcome of Patients with Germinal Center and Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Chemo-Immunotherpy". Blood 116, n.º 21 (19 de novembro de 2010): 3130. http://dx.doi.org/10.1182/blood.v116.21.3130.3130.
Texto completo da fonteTarius, Jenifer Marsela, Hermawan Istiadi, Ika Pawitra Miranti e Intan Rahmania Eka Dini. "THE CORRELATION BETWEEN CELL OF ORIGIN SUBTYPE WITH OVERALL SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG". DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) 9, n.º 3 (12 de maio de 2020): 252–58. http://dx.doi.org/10.14710/dmj.v9i3.27504.
Texto completo da fonteGandhi, Shipra, Vishala T. Neppalli, George Deeb, Myron S. Czuczman e Francisco J. Hernandez-Ilizaliturri. "Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 122, n.º 21 (15 de novembro de 2013): 5064. http://dx.doi.org/10.1182/blood.v122.21.5064.5064.
Texto completo da fonteHayama, Miyuki, Masataka Okamoto, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima e Nozomi Niitsu. "Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era." Blood 116, n.º 21 (19 de novembro de 2010): 1800. http://dx.doi.org/10.1182/blood.v116.21.1800.1800.
Texto completo da fonteKharchenko, Yevgeniya, Tatyana Semiglazova, Anna Artemeva, Galina Kireeva, I. Polyatskin, Ilya Zyuzgin, Larisa Filatova, Yuliya Chudinovskikh, Margarita Motalkina e Yuliya Oleynik. "PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA". Problems in oncology 66, n.º 1 (1 de janeiro de 2020): 79–89. http://dx.doi.org/10.37469/0507-3758-2020-66-1-79-89.
Texto completo da fonteAdhi Pangarsa, Eko, Desta Nur Ewika Ardini, Daniel Rizky, Kevin Tandarto, Hermawan Istiadi, Dik Puspasari, Budi Setiawan et al. "The association of Hypoxia-Inducible Factor-2α (HIF-2α) overexpression score with Germinal Center B-Cell Like (GCB) and Non-Germinal Center B-Cell Like (Non-GCB) subtypes of Diffuse Large B-cell Lymphoma (DLBCL)". Bali Medical Journal 12, n.º 3 (22 de agosto de 2023): 2456–62. http://dx.doi.org/10.15562/bmj.v12i3.4521.
Texto completo da fonteMishima, Yuko, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano et al. "R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL". Blood 126, n.º 23 (3 de dezembro de 2015): 1507. http://dx.doi.org/10.1182/blood.v126.23.1507.1507.
Texto completo da fonteChavez, Julio, Mark Walsh, Francisco J. Hernandez-Ilizaliturri, Anjana Elefante e Myron S. Czuczman. "Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy." Blood 114, n.º 22 (20 de novembro de 2009): 623. http://dx.doi.org/10.1182/blood.v114.22.623.623.
Texto completo da fonteVan Meerten, Tom, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls e Edwin Bremer. "CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 132, Supplement 1 (29 de novembro de 2018): 2852. http://dx.doi.org/10.1182/blood-2018-99-114561.
Texto completo da fonteNiitsu, Nozomi, Naoki Takahashi, Tadashi Yoshino, Masataka Okamoto e Shigeo Nakamura. "Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era". Blood 126, n.º 23 (3 de dezembro de 2015): 3911. http://dx.doi.org/10.1182/blood.v126.23.3911.3911.
Texto completo da fonteAlam, SM Mahbubul, e Ahmed Khaled. "Immunophenotypic characteristics of Diffuse Large Bcell Lymphoma". Bioresearch Communications 8, n.º 1 (26 de dezembro de 2021): 1049–52. http://dx.doi.org/10.3329/brc.v8i1.57043.
Texto completo da fonteNooruddin, Zohra, Zenggang Pan, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, Daniel A. Pollyea, Jonathan A. Gutman et al. "Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes". Blood 128, n.º 22 (2 de dezembro de 2016): 3054. http://dx.doi.org/10.1182/blood.v128.22.3054.3054.
Texto completo da fonteSlimani, Yasmine, Fouzia Hali e Fatima-Zohra El Fatoiki. "Triple-negative diffuse large B-cell lymphoma: A distinct entity". Our Dermatology Online 12, n.º 4 (19 de outubro de 2021): 427–29. http://dx.doi.org/10.7241/ourd.20214.17.
Texto completo da fonteLossos, Izidore S., XiaoQing Lu, Feiying Ding, Manuel Rosado, Ash A. Alizadeh e Hovav Nechushtan. "Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions." Blood 104, n.º 11 (16 de novembro de 2004): 244. http://dx.doi.org/10.1182/blood.v104.11.244.244.
Texto completo da fonteCosta, Luciano J., Andrew L. Feldman, Ivana N. Micallef, David J. Inward, Patrick B. Johnston, Luis F. Porrata, Mark R. Litzow e Stephen M. Ansell. "Germinal Center B Cell and Non-Germinal Center B Cell-Like DLBCL Have Similar Clinical Features at the Time of Progression and Comparable Outcome Following Autologous HSC Transplantation." Blood 110, n.º 11 (16 de novembro de 2007): 1901. http://dx.doi.org/10.1182/blood.v110.11.1901.1901.
Texto completo da fonteJulianty, Patricia Fransisca, Maria Francisca Ham, Kusmardi Kusmardi e Agnes Stephanie Harahap. "CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma". Open Access Macedonian Journal of Medical Sciences 8, B (17 de abril de 2020): 375–80. http://dx.doi.org/10.3889/oamjms.2020.4645.
Texto completo da fonteLenz, Georg, George Wright, Sandeep Dave, Alexander Kohlmann, Wenming Xiao, John Powell, Hong Zhao et al. "Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy." Blood 110, n.º 11 (16 de novembro de 2007): 348. http://dx.doi.org/10.1182/blood.v110.11.348.348.
Texto completo da fonteNechushtan, Hovav, Joseph D. Rosenblatt e Izidore S. Lossos. "IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently." Blood 104, n.º 11 (16 de novembro de 2004): 242. http://dx.doi.org/10.1182/blood.v104.11.242.242.
Texto completo da fonteLocatelli, Silvia L., Roberto Papait, Giuseppa Careddu, Ada Koschorke, Giuliano G. Stirparo, Monica Balzarotti, Luca Castagna, Armando Santoro e Carmelo Carlo-Stella. "Upregulation of Cereblon Expression By the DNA Methyltransferase Inhibitor Azacytidine Strongly Enhances Lenalidomide Cytotoxicity in Germinal Center B-Cell-like (GCB) and Activated B-Cell-like (ABC) Diffuse Large B-Cell Lymphoma (DLBCL)". Blood 124, n.º 21 (6 de dezembro de 2014): 2253. http://dx.doi.org/10.1182/blood.v124.21.2253.2253.
Texto completo da fonteKleinstern, Geffen, Dennis P. Robinson, Lisa M. Rimsza, Melissa C. Larson, Rebecca L. King, Grzegorz S. Nowakowski, Carrie A. Thompson et al. "Abstract 741: Evaluation of etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 741. http://dx.doi.org/10.1158/1538-7445.am2022-741.
Texto completo da fonteFu, Kai, Dennis D. Weisenburger, William W. L. Choi, Kyle D. Perry, Lynette M. Smith, Xinlan Shi, Christine P. Hans et al. "Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma". Journal of Clinical Oncology 26, n.º 28 (1 de outubro de 2008): 4587–94. http://dx.doi.org/10.1200/jco.2007.15.9277.
Texto completo da fonteCao, Yabing, Ying Huang, Sheng Ye e Tongyu Lin. "Prognostic impact of immunohistochemically defined germinal center B-cell and nongerminal center B-cell subtypes of diffuse large B-cell lymphoma in rituximab era." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e18517-e18517. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18517.
Texto completo da fonteHuang, Ying, Sheng Ye, Yabing Cao, Zhiming Li, Jiajia Huang, He Huang, Muyan Cai, Rongzhen Luo e Tongyu Lin. "Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients". Scientific World Journal 2012 (2012): 1–7. http://dx.doi.org/10.1100/2012/897178.
Texto completo da fonteDunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Dave, George Wright, Nicole Grant, Margaret Shovlin et al. "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma". Blood 113, n.º 24 (11 de junho de 2009): 6069–76. http://dx.doi.org/10.1182/blood-2009-01-199679.
Texto completo da fonteWenzl, Kerstin, Bryce Manso, Yan W. Asmann, Matthew J. Maurer, Michelle Manske, Zhi-Zhang Yang, Susan L. Slager et al. "Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma". Blood 128, n.º 22 (2 de dezembro de 2016): 2935. http://dx.doi.org/10.1182/blood.v128.22.2935.2935.
Texto completo da fonteDe Paepe, Pascale, Ruth Achten, Gregor Verhoef, Iwona Wlodarska, Michel Stul, Vera Vanhentenrijk, Marleen Praet e Chris De Wolf-Peeters. "Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas". Journal of Clinical Oncology 23, n.º 28 (1 de outubro de 2005): 7060–68. http://dx.doi.org/10.1200/jco.2005.15.503.
Texto completo da fonteDekker, Joseph D., Daechan Park, Arthur L. Shaffer, Holger Kohlhammer, Wei Deng, Bum-Kyu Lee, Gregory C. Ippolito et al. "Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1". Proceedings of the National Academy of Sciences 113, n.º 5 (19 de janeiro de 2016): E577—E586. http://dx.doi.org/10.1073/pnas.1524677113.
Texto completo da fonteWaller, Rosalie Griffin, Dennis P. Robinson, Anne J. Novak, Lisa M. Rimsza, Kerstin Wenzl, Rebecca L. King, Andrew L. Feldman et al. "Abstract 1181: Etiologic heterogeneity of genetic risk for DLBCL cell-of origin molecular subtypes". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1181. http://dx.doi.org/10.1158/1538-7445.am2023-1181.
Texto completo da fonteKim, Yu Ri, Soo-Jeong Kim, June-Won Cheong, Yundeok Kim, Ji Eun Jang, Jung Yeon Lee, Deok-Hwan Yang et al. "Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase". Blood 124, n.º 21 (6 de dezembro de 2014): 3998. http://dx.doi.org/10.1182/blood.v124.21.3998.3998.
Texto completo da fonteSoo, Joanne, David Matthew Kurtz, Florian Scherer, Alexander F. M. Craig, Michael C. Jin, Jason R. Westin, Davide Rossi et al. "Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA." Journal of Clinical Oncology 35, n.º 15_suppl (20 de maio de 2017): 7538. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7538.
Texto completo da fonteXu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand et al. "Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma". Blood 128, n.º 26 (29 de dezembro de 2016): 3083–100. http://dx.doi.org/10.1182/blood-2016-05-715094.
Texto completo da fonteFoureau, David, Lawrence J. Druhan, Nury M. Steuerwald, Sarah A. Baxter, Omotayo O. Fasan, Belinda R. Avalos e Nilanjan Ghosh. "Cytokine Profiling of ABC-Subtype and GCB-Subtype Diffuse Large B Cell Lymphoma: Systemic Nfkb Activation and Impact on Myeloid-Derived Suppressor Cells Distribution". Blood 126, n.º 23 (3 de dezembro de 2015): 2666. http://dx.doi.org/10.1182/blood.v126.23.2666.2666.
Texto completo da fonteHavranek, Ondrej, Jingda Xu, Stefan Koehrer, Zhiqiang Wang, Justin M. Comer, Lisa Becker, Allen F. Yi et al. "Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition". Blood 128, n.º 22 (2 de dezembro de 2016): 779. http://dx.doi.org/10.1182/blood.v128.22.779.779.
Texto completo da fonteTakizawa, Jun, Sadao Aoki, Akihito Momoi, Toshiki Kitajima, Masutaka Higashimura, Naoya Nakamura e Yoshifusa Aizawa. "BCL6 Rearrangement Detected by FISH Analysis Is a Poor Prognostic Factor in the “Non-Germinal Center Phenotype” of Diffuse Large B-Cell Lymphoma." Blood 108, n.º 11 (16 de novembro de 2006): 4620. http://dx.doi.org/10.1182/blood.v108.11.4620.4620.
Texto completo da fonteGupta, Mamta, Guangzhen Hu, Steven Offer, Matthew J. Maurer, Linda Wellik, Jing Jing Han, Ahmet Dogan, Robert B. Diasio e Thomas E. Witzig. "Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes." Blood 120, n.º 21 (16 de novembro de 2012): 2655. http://dx.doi.org/10.1182/blood.v120.21.2655.2655.
Texto completo da fonteZhao, Fengyi, Lei Zhang, Yan Qin, Ming-Zhe Han, Xiaohong Han, Shiyu Jiang e Yuankai Shi. "Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis". Blood 134, Supplement_1 (13 de novembro de 2019): 1243. http://dx.doi.org/10.1182/blood-2019-131656.
Texto completo da fonteAlcoceba, Miguel, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig et al. "Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma". Blood 120, n.º 21 (16 de novembro de 2012): 1589. http://dx.doi.org/10.1182/blood.v120.21.1589.1589.
Texto completo da fonteNowakowski, Grzegorz S., Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson et al. "Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study". Journal of Clinical Oncology 33, n.º 3 (20 de janeiro de 2015): 251–57. http://dx.doi.org/10.1200/jco.2014.55.5714.
Texto completo da fonteGozgit, Joseph M., Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning e Victor M. Rivera. "Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models". Blood 126, n.º 23 (3 de dezembro de 2015): 4000. http://dx.doi.org/10.1182/blood.v126.23.4000.4000.
Texto completo da fonteZettl, Andreas, Silvia Bea, George Wright, Itziar Salaverria, Philipp Jehn, German Ott, Wing-Chung Chan et al. "Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work)." Blood 104, n.º 11 (16 de novembro de 2004): 415. http://dx.doi.org/10.1182/blood.v104.11.415.415.
Texto completo da fonteCao, Y., T. Lin, S. Wang, X. Fu, J. Xiao, J. Yi, H. Lin e Z. Guan. "A phase II study of R-CHOP in treatment of diffuse large B-cell lymphoma (DLBCL) subgroups". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junho de 2006): 17540. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.17540.
Texto completo da fonteZhao, Peiqi, Huilai Zhang, Kai Fu, Xianhuo Wang, Lanfang Li, Zhengzi Qian, Lihua Qiu e Shiyong Zhou. "CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma". Blood 134, Supplement_1 (13 de novembro de 2019): 4117. http://dx.doi.org/10.1182/blood-2019-127666.
Texto completo da fonteWang, Y. Lynn, Jiao Ma, Wei Xing, Pin Lu, Karen Dresser, Ailin Guo, Anjali Pandey, Pamela B. Conley, Hongbo Yu e Greg Coffey. "SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor". Blood 124, n.º 21 (6 de dezembro de 2014): 926. http://dx.doi.org/10.1182/blood.v124.21.926.926.
Texto completo da fonteFeng, Ru, Xiaolei Wei, Meng Xu, Fen Huang, Yongqiang Wei, Tong Zhao e B. Hilda Ye. "STAT3 Predicts Poor Outcome In Patients With Advanced Diffuse Large B Cell Lymphoma". Blood 122, n.º 21 (15 de novembro de 2013): 5069. http://dx.doi.org/10.1182/blood.v122.21.5069.5069.
Texto completo da fonteQu, Jie, Matthew J. Maurer, James R. Cerhan, Anne J. Novak, Thomas M. Habermann, William R. Macon, Andrew L. Feldman et al. "Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL". Blood 128, n.º 22 (2 de dezembro de 2016): 5299. http://dx.doi.org/10.1182/blood.v128.22.5299.5299.
Texto completo da fonteEnnishi, Daisuke, Ali Bashashati, Saeed Saberi, Anja Mottok, Barbara Meissner, Merrill Boyle, Susana Ben-Neriah et al. "Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma". Blood 128, n.º 22 (2 de dezembro de 2016): 607. http://dx.doi.org/10.1182/blood.v128.22.607.607.
Texto completo da fontePrakash, Gaurav, Atul Sharma, Vinod Raina, Lalit Kumar e Mehar C. Sharma. "Outcome in different molecular subtypes of diffuse large B-cell lymphoma: Indian experience." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e18518-e18518. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18518.
Texto completo da fonteYunalda, Indah, Krisna Murt, Aida Farida, Ika Kartika e Erial Bahar. "Density of CD8 in Tumor Microenvironment of Diffuse Large B Cell Lymphoma Subtypes". Majalah Patologi Indonesia 30, n.º 2 (1 de maio de 2021): 227–33. http://dx.doi.org/10.55816/mpi.v30i2.466.
Texto completo da fonteTatterton, Dylan J., Benjamin Sale, Joel Allen, Maddy L. Newby, Giorgia Chiodin, Patrick J. Duriez, John Butler et al. "Oligomannose-Type Glycans in the Antigen Binding Site Identify Origin and Prognosis of Diffuse Large B Cell Lymphoma". Blood 142, Supplement 1 (28 de novembro de 2023): 428. http://dx.doi.org/10.1182/blood-2023-188721.
Texto completo da fonteFu, K., K. D. Perry, L. M. Smith, C. P. Hans, T. C. Greiner, W. C. Chan, D. D. Weisenburger et al. "Effect of addition of rituximab to CHOP on survival of patients in both the GCB and non-GCB subgroups of diffuse large B-cell lymphoma". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junho de 2007): 8040. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8040.
Texto completo da fonte